ReviewCancers2021
Chemotherapy in Neuroendocrine Tumors.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Consensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms.Annals of surgical oncology · 2026Article
- Article
- Concurrent pancreatic ductal adenocarcinoma and poorly differentiated neuroendocrine carcinoma: A case report and review of the literature.International journal of surgery case reports · 2025Article
- Neuroendocrine Breast Cancer-Associated Ectopic Adrenocorticotropic Hormone Syndrome Requiring Bilateral Adrenalectomy.Current oncology (Toronto, Ont.) · 2025Article
- Real-world outcomes of metastatic cancer patients hospitalized at initial diagnosis: ONIRIS, a national study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Cellular mechanisms of hormone secretion in neuroendocrine tumors: what goes wrong?Frontiers in cell and developmental biology · 2025Review
- Current Status of Immunotherapy in Management of Small Bowel Neuroendocrine Tumors.Current oncology reports · 2024Review
- An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and Prospects.International journal of molecular sciences · 2024Review
- Managing end-stage carcinoid heart disease: A case report and literature review.World journal of gastrointestinal oncology · 2024Article
- Article
- The incidence, prevalence, and survival analysis of pancreatic neuroendocrine tumors in the United States.Journal of endocrinological investigation · 2023Article
- Neuroendocrine Tumors: Genomics and Molecular Biomarkers with a Focus on Metastatic Disease.Cancers · 2023Review
- Emerging Immunotherapeutic and Diagnostic Modalities in Carcinoid Tumors.Molecules (Basel, Switzerland) · 2023Review
- Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade.Frontiers in endocrinology · 2023Review
- Platin‑based chemotherapy does not improve survival in patients with non‑metastatic resected typical carcinoid tumors.Molecular and clinical oncology · 2022Article
- Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role for cytotoxic chemotherapy in patients with well-differentiated neuroendocrine tumors (NETs) remains debated. Compared to patients with poorly differentiated neuroendocrine carcinomas (NECs) where chemotherapy is utilized ubiquitously, chemotherapy may play a more select role in patients with certain types of NETs (e.g., pancreatic tumors, higher grade tumors, and tumors possessing DNA damage repair defects). The primary types of chemotherapy that have been tested in patients with NETs include alkylating agent- and platinum agent-based combinations. Across regimens, chemotherapy appears to elicit greater antitumor activity in patients with pancreatic or grade 3 NETs. The role for chemotherapy in lower grade extra-pancreatic NETs remains undefined. Furthermore, while chemotherapy has demonstrated clinically meaningful benefit for patients in the systemic setting, its role in the adjuvant or neoadjuvant setting is as-of-yet undetermined. Finally, efforts to combine chemotherapy with targeted therapy and peptide receptor radionuclide therapy are ongoing, in hopes of improving the cytoreductive treatment options for patients with NETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.